Combination regimens as potential treatment of non-small-cell lung cancer patients with HER2 mutation in the real world: a multicenter study
Combination regimens, especially C + I + A, significantly improve PFS and offer superior therapeutic benefits for patients with HER2-mutated NSCLC compared to single chemotherapy or immunotherapy or TKIs treatments.
Authors
- Zhengbo Song
- Tangfeng Lv (ORCID: https://orcid.org/0000-0001-7224-8468)
- Yue Hao (ORCID: https://orcid.org/0000-0002-4725-6084)
- Qian Wang (ORCID: https://orcid.org/0000-0002-1201-865X)
- Ke Wang (ORCID: https://orcid.org/0000-0002-2824-1047)
- Dong Wang (ORCID: https://orcid.org/0000-0003-2475-0642)
- Yong Ping Song
- Chunwei Xu
- Chengyu Chen
Institutions
- Nanjing University of Chinese Medicine (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Zhejiang Cancer Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251338397
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00